Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies

Simple item page
dc.contributor.authorUlloa, Camilo
dc.contributor.authorAnglicheau, Dany
dc.contributor.authorSnanoudj, Renaud
dc.contributor.authorScemla, Anne
dc.contributor.authorMartinez, Frank
dc.contributor.authorTimsit, Marc-Olivier
dc.contributor.authorLegendre, Christophe
dc.contributor.authorSberro, Rebecca
dc.date.accessioned2022-07-05T15:51:40Z
dc.date.available2022-07-05T15:51:40Z
dc.date.issued2019
dc.description.abstractBackground: Belatacept could be the treatment of choice in renal-transplant recipients with renal dysfunction attributed to calcineurin inhibitor (CNI) nephrotoxicity. Few studies have described its use in patients with donor-specific antibody (DSA). Methods: We retrospectively evaluated conversion from CNIs to belatacept in 29 human leukocyte antigen-immunized renal-transplant recipients. Data about acute rejection, DSA, and renal function were collected. These patients were compared with 42 nonimmunized patients treated with belatacept. Results: Patients were converted from CNIs to belatacept a median of 444 days (interquartile range, 85-1200) after transplantation and were followed up after belatacept conversion, for a median of 308 days (interquartile range, 125-511). At conversion, 16 patients had DSA. Nineteen DSA were observed in these 16 patients, of which 11/19 were <1000 mean fluorescence intensity (MFI), 7/19 were between 1000 and 3000 MFI, and one was >3000 MFI. At last follow-up, preexisting DSA had decreased or stabilized. Seven patients still had DSA with a mean MFI of 1298 ± 930 at the last follow-up. No patient developed a de novo DSA in the DSA-positive group. In the nonimmunized group, one patient developed de novo DSA (A24-MFI 970; biopsy for cause did not show biopsy-proven acute rejection or microinflammation score). After belatacept conversion, one antibody-mediated rejection was diagnosed. The mean estimated glomerular filtration rate improved from 31.7 ± 14.2 mL/min/1.73 m to 40.7 ± 12.3 mL/min/1.73 m (P < 0.0001) at 12 months after conversion. We did not find any significant difference between groups in terms of renal function, proteinuria, or biopsy-proven acute rejection. Conclusions: We report on a safe conversion to belatacept in human leukocyte antigen-immunized patients with low DSA levels.es
dc.description.versionVersión publicadaes
dc.identifier.citationUlloa CE, Anglicheau D, Snanoudj R, Scemla A, Martinez F, Timsit MO, Legendre C, Sberro-Soussan R. Conversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodies. Transplantation. 2019 Oct;103(10):2150-2156. doi:10.1097/TP.0000000000002592.es
dc.identifier.urihttps://doi.org/10.1097/TP.0000000000002592es
dc.identifier.urihttp://hdl.handle.net/11447/6296
dc.language.isoenes
dc.subjectAbatacept / administration & dosagees
dc.subjectCalcineurin Inhibitors / administration & dosagees
dc.subjectCalcineurin Inhibitors / adverse effectses
dc.subjectDrug Substitutiones
dc.subjectAllografts / drug effectses
dc.subjectCalcineurin Inhibitors / adverse effectses
dc.subjectGlomerular Filtration Rate / drug effectses
dc.subjectGlomerular Filtration Rate / immunologyes
dc.subjectGraft Rejection / drug therapyes
dc.subjectGraft Rejection / immunologyes
dc.subjectGraft Rejection / pathologyes
dc.subjectHLA Antigens / immunologyes
dc.subjectIsoantibodies / bloodes
dc.subjectIsoantibodies / immunologyes
dc.subjectIsoantigens / immunologyes
dc.subjectKidney / drug effectses
dc.subjectKidney / immunologyes
dc.subjectKidney Transplantation / adverse effectses
dc.subjectRenal Insufficiency / chemically inducedes
dc.subjectRenal Insufficiency / prevention & controles
dc.titleConversion From Calcineurin Inhibitors to Belatacept in HLA-sensitized Kidney Transplant Recipients With Low-level Donor-specific Antibodieses
dc.title.alternativeConversión de inhibidores de calcineurina a belatacept en receptores de trasplante de riñón sensibilizados con HLA con anticuerpos específicos del donante de bajo niveles
dc.typeArticlees
dcterms.sourceTransplantationes

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Conversion from calcineurin inhibitors to belatacept in HLA.pdf
Size:
310.09 KB
Format:
Adobe Portable Document Format
Description:
Texto completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services